Audience: Accredited for Pharmacists UAN: 0837-0000-26-039-L01-P
Pharmacists objectives:
Describe key updates and recommendations within the 2025 ATS community-acquired pneumonia (CAP) guidelines and the 2025 IDSA complicated urinary tract infection (cUTI) guidelines.
Analyze empiric and definitive antimicrobial therapy options for CAP and complicated UTI with respect to spectrum of activity, resistance risk, and guideline concordance.
Apply guideline-based recommendations to select appropriate antimicrobial regimens based on patient-specific factors, microbiology data, and stewardship principles.
Evaluate antimicrobial regimens for CAP and complicated UTI to reduce unnecessary broad-spectrum use, adverse effects, and antimicrobial resistance while maintaining clinical effectiveness.
Attendee Fees: Free for members, $10 for non-members